PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: ...

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...

Therapeutics trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Equities researchers at HC Wainwright boosted their Q2 2025 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst E. Bodnar ...

BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a ...

Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...

BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has ...

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...